0.675
Prelude Therapeutics Inc stock is traded at $0.675, with a volume of 185.89K.
It is down -4.67% in the last 24 hours and down -8.78% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$0.7081
Open:
$0.7001
24h Volume:
185.89K
Relative Volume:
0.75
Market Cap:
$37.23M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.3792
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
-15.59%
1M Performance:
-8.78%
6M Performance:
-66.25%
1Y Performance:
-85.76%
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PRLD
Prelude Therapeutics Inc
|
0.675 | 37.23M | 0 | -131.52M | -107.56M | -1.78 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jul-29-22 | Initiated | Jefferies | Buy |
Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
Apr-26-21 | Initiated | H.C. Wainwright | Buy |
Mar-09-21 | Initiated | Barclays | Overweight |
Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
Oct-20-20 | Initiated | BofA Securities | Buy |
Oct-20-20 | Initiated | Goldman | Neutral |
Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech
Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo Finance
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Prelude Therapeutics stock surges on insider buying - Investing.com
Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com Australia
Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa
Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com
Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com
Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa
Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock - Investing.com India
Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock By Investing.com - Investing.com Australia
Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase - Investing.com Australia
Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase By Investing.com - Investing.com South Africa
Prelude Therapeutics’ SWOT analysis: biotech stock faces mixed outlook amid clinical trials - Investing.com Australia
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial - MyChesCo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares By Investing.com - Investing.com South Africa
Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares - Investing.com
Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements - MyChesCo
Rhumbline Advisers Purchases 154,826 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Reports 2024 Financial Results - TipRanks
Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77) - TipRanks
Prelude Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Prelude Therapeutics Inc SEC 10-K Report - TradingView
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewswire
PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MyChesCo
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo
Prelude Therapeutics to Present at Barclays Global Healthcare Conference - MSN
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MyChesCo
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
How Will Prelude's Cancer Pipeline Updates Impact Investors at Upcoming Barclays Conference? - StockTitan
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MyChesCo
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Yahoo Finance
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN
PRLD stock touches 52-week low at $0.79 amid market challenges - Investing.com
Palvella Therapeutics to Present at TD Cowen 45th Annual Healthcare Conference - MyChesCo
Context Therapeutics Grants Stock Options to New Employees - MyChesCo
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MyChesCo
Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat - MyChesCo
Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Thursday - Defense World
Delaware weekly roundup: The Eagles’ River; CAFE opens apps; Prelude Therapeutics hires CFO - Technical.ly
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results - MyChesCo
Prelude Therapeutics Names Bryant Lim As Permanent CFO -February 05, 2025 at 06:35 pm EST - Marketscreener.com
Prelude Therapeutics Appoints Bryant D. Lim as CFO - TipRanks
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prelude Therapeutics Inc Stock (PRLD) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):